Bioverativ (NASDAQ: BIVV) is an independent, global biotechnology company focused on the discovery, development and commercialization of therapies for hemophilia and other rare blood disorders.

Biogen has initiated the transfer and is providing assistance with obtaining various assets and licenses, including for ELOCTATE® and ALPROLIX®. Until the transfers are completed, Bioverativ and Biogen will each have a relationship to the products. Biogen will also continue to manufacture these treatments.


Cost Basis Post Spin-off

SEC Filings